Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia

    ... of adequate method of contraception are shown in the protocol section 4.1.10 Women are considered post-menopausal and not of ... Patients unwilling or unable to comply with the protocol . Pregnant or breastfeeding Acute promyelocytic leukemia ...

    Clinical Trial last updated 06/06/2016 - 1:26pm.

  2. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects with PNH

    ... pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study Males must agree to use protocol defined methods of contraception and agree to refrain from donating ...

    Clinical Trial last updated 07/19/2016 - 12:46pm.

  3. Transplants With Unlicensed Preserved Cord Blood

    ... if the transplant will occur under an IND research protocol . These units are in current and future inventory at domestic and ... Indications. This study is an access and distribution protocol conducted by the National Marrow Donor Program (NMDP) for unlicensed ...

    Clinical Trial last updated 04/27/2016 - 3:20pm.

  4. Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies

    ... C, but have a negative viral load, are eligible. f. The protocol chairman will determine the eligibility of patients related to ... antimicrobial agents after seven days of therapy. The Protocol PI is the final arbiter of eligibility. Pleural/pericardial ...

    Clinical Trial last updated 06/06/2016 - 1:18pm.

  5. Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

    ... allogeneic peripheral blood stem cell (PBSC) transplant protocol (03-H-0170) for patients with severe sickle cell disease (SCD) and ... (and reduce the transplant failure rate) in this new protocol, we will continue our nonmyeloablative approach in the patients with ...

    Clinical Trial last updated 04/28/2016 - 9:09am.

  6. Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

    ... in patients up to the time they begin therapy under this protocol Patients < 12 yrs of age must be discussed on a case by case basis with the primary investigator (PI) of the protocol prior to registration A signed informed consent form or minor ...

    Clinical Trial last updated 04/28/2016 - 2:45pm.

  7. Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic

    ... Able and willing to comply with the requirements of the protocol . Able to understand and willing to sign an IRB-approved ... by the allowed medications permitted in the study protocol that would preclude safe and complete study participation, as ...

    Clinical Trial last updated 04/29/2016 - 4:33pm.

  8. T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

    ... The primary aim of this protocol is to evaluate if the one-year survival is significantly improved ...

    Clinical Trial last updated 05/03/2016 - 11:43am.

  9. Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

    ... by cardiology or pulmonary prior to enrollment on this protocol Serum creatinine =<1.5 mg/dL or creatinine clearance > 50 ... some patients with minor deviations may be accepted on protocol after discussion with the principal investigator (PI) Serum ...

    Clinical Trial last updated 05/23/2016 - 2:06pm.

  10. HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

    ... The trial proposed is a three arm phase II treatment protocol designed to investigate the safety and efficacy of risk-adjusted ...

    Clinical Trial last updated 04/28/2016 - 8:44am.